Conferences

CONFERENCE

AMP 2020 Virtual Meeting & Expo

November 16 - 20, 2020, Virtual

Read More

November 16-20th – Join us for this year’s Association for Molecular Pathology (AMP) Virtual Education and Networking Experience. Watch the Corporate Workshop on-demand here

News & Press

Fabric Genomics, a global computational genomics company offering data analysis and clinical reporting tools, announced today that it has partnered with data management company ITTM S.A. (Information Technology for Translational Medicine) to provide secure genomic data hosting capabilities for EU customers. By combining Fabric Genomics’ leading analysis tools with ITTM’s proven secure hosting and infrastructure …

Read More

Fabric Genomics, a global computational genomics company, and TOMA Biosciences, a genomic cancer diagnostics company, announced today a partnership that will bring together premier chemistry and informatics platforms for deepened genomic analysis of cancer and delivery of clinically meaningful information for tumor profiling. The companies will co-develop an end-to-end oncology genomic testing and clinical interpretation …

Read More

Fabric Genomics, a global computational genomics company, and Veritas Genetics, the global leader in genetic sequencing and interpretation, announced today at the ACMG Annual Clinical Genetics Meeting that they have entered into a technology partnership. The goal of the collaboration is to accelerate Veritas’ myGenome product for personal whole genome sequencing using Fabric Genomics’ new …

Read More

Fabric Genomics, a global computational genomics company, and Sentieon, which develops highly optimized algorithms for bioinformatics applications, today announced a technology partnership that will enhance Fabric Genomics’ secondary analysis capabilities within Fabric Enterprise™, the company’s new end-to-end precision medicine platform. Fabric Genomics’ new secondary analysis offering, Fabric Standard™, is 10 times faster than commonly adopted …

Read More

Omicia, Inc., a leading provider of clinical genomic data analysis and reporting tools, was selected to join the Cancer Moonshot’s Blood Profiling Atlas in Cancer (Blood PAC) consortium. In joining Blood PAC, Omicia is demonstrating its commitment to advancing cancer genetics research and extending patients’ lives. The Blood PAC was formed in October 2016 in …

Read More

Omicia, Inc., a leading provider of clinical genome interpretation and reporting software, announced today that San Diego-based Rady Children’s Institute for Genomic Medicine has chosen the company as their first line genome interpretation partner for the implementation of Rady Children’s rapid genome testing in their neonatal and pediatric intensive care units (NICU/ PICU). Stephen Kingsmore, …

Read More

Omicia, Inc., a leading provider of clinical genome interpretation and reporting software, announced today that it has delivered more than 500 clinical reports for the 100,000 Genomes Project, and has begun to return clinical reports for the project’s main program. These clinical reports are being delivered to Genomics England, leader of the 100,000 Genomes Project, and …

Read More

In the recent article “The DNA of a Nation,” Nature magazine highlights the highly-specialized and dedicated clinical interpretation services that Genomics England requires for their 100,000 Genomes Project, which is the first step in bringing genomics to the UK healthcare system. Omicia, the worldwide leader in genome informatics and clinical interpretation, was selected from 28 …

Read More

Omicia, Inc., a leading provider of clinical genome interpretation and reporting software, today announced the completion of a $23 million Series B financing round. Several new investors participated in the round, including UPMC Enterprises, Roche Venture Fund, LDV Partners, Ping An Ventures, and a large genomics investor, as well as existing investors ARTIS Ventures, Acadia …

Read More

Omicia announces the launch of its new ACMG-scoring module for the Opal Clinical™ interpretation and reporting software platform at the 2016 ACMG Annual Clinical Genetics Meeting. This functionality provides an intuitive interface and workflow for clinical testing labs to systematically assess the disease-causing potential of genetic variants using the evidence-based classification system defined in the …

Read More
PRESS | August 27, 2015

The United Kingdom aims to sequence 100,000 human genomes by 2017. But screening them for disease-causing variants will require innovative software. For the 100,000 Genomes Project, it will use Omicia’s Opal Clinical genome interpretation software to assess which variants are likely to be causing disease.  

Read More

Rare Genomics Institute (RG) is an international non-profit that that makes cutting edge research technologies of genome sequencing, physicians and scientists around the world accessible to rare disease patients. In partnership with RG, Omicia is delighted to announce the recipients of this year’s BeHEARD Rare Disease Science Challenge, who will receive free access to Omicia’s …

Read More

Genomics England announce that it will be using technology co-developed in a partnership between Omicia and the University of Utah, and exclusively commercialized through Omicia, to interpret the DNA of Britons as part of the 100,000 Genomes Project, a national effort to hasten creation of diagnostics and treatments that are tailored to a person’s genetic …

Read More

Omicia has been selected as a finalist for the Innovation Showcase at VentureBeat’s HealthBeat 2014 event.  As one of 10 finalists selected from dozens of startups in the digital health space, Omicia will have the opportunity to demonstrate how Opal Clinical will improve patient outcomes by increasing the accuracy, speed, and diagnostic yield of NGS …

Read More